Conduit Pharmaceuticals (CDT) announces the filing of four new patent applications relating to its key assets AZD1656 and AZD5658, including the Company’s first patent filings for AZD5658. These filings represent a significant expansion of Conduit’s intellectual property portfolio, further supporting its strategy to advance and license differentiated, IP-rich pharmaceutical assets. The new patents reflect combinations of Conduit’s lead assets with existing therapies, identified through extensive AI-led analysis conducted in collaboration with Sarborg. This partnership continues to yield valuable insights, enabling the Company to generate novel, data-driven IP with strong strategic and commercial relevance.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDT:
- Conduit Pharmaceuticals Enters Joint Development Agreement
- Conduit Pharmaceuticals enters joint development agreement with Manoira
- Conduit Pharmaceuticals Sets 2025 Annual Meeting Date
- Conduit Pharmaceuticals approved to transfer listing to Nasdaq Capital Market
- Conduit Pharmaceuticals regains Nasdaq compliance